UPDATE: Morgan Stanley Initiates Intermolecular at Equal-Weight on Elpida Bankruptcy

Morgan Stanley initiates its coverage on Intermolecular IMI with an Equal-weight rating and no price target. Morgan Stanley says, "We like the fundamental value proposition and see long-term value in the shares. However, uncertainty around Elpida's bankruptcy remains a near-term overhang. We conservatively budget for Elpida to hinder high margin royalty revenues, and delay royalty revenues into late CY14." IMI closed at $6.91 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetInitiationPre-Market OutlookAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!